Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037917 | 0.75 | TSHR (0.38) | FAAHMGLLCYP19A1CYP3A4TP53 | |
| SCHEMBL4043279 | 0.72 | FAAH (0.36) | FAAHMGLLCYP19A1TP53TSHR | |
| SCHEMBL6235468 | 0.69 | CYP19A1 (0.33) | FAAHMGLLCYP19A1CYP3A4TP53 | |
| SCHEMBL3947334 | 0.63 | CYP19A1 (0.32) | FAAHCYP19A1 | |
| SCHEMBL6398205 | 0.63 | LMNA (0.38) | FAAHMGLLCYP3A4TSHRLMNA | |
| SCHEMBL4185530 | 0.63 | FAAH (0.39) | FAAHMGLLCYP3A4TSHRLMNA | |
| SCHEMBL7563095 | 0.61 | MAPK1 (0.39) | FAAHMGLLCYP19A1CYP3A4TP53 | |
| SCHEMBL4194016 | 0.61 | GAA (0.40) | FAAHMGLLCYP3A4LMNAMAPK1 | |
| SCHEMBL30900666 | 0.60 | CYP19A1 (0.32) | FAAHMGLLCYP19A1 | |
| SCHEMBL10547797 | 0.60 | CYP3A4 (0.35) | FAAHMGLLCYP19A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | FAAH 2820/4885MGLL 4115/4885CYP19A1 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.